Research Papers:

Selection of a novel CD19 aptamer for targeted delivery of doxorubicin to lymphoma cells

Yan Hu, Xiaoou Li, Yacong An, Jinhong Duan and Xian-Da Yang _

PDF  |  HTML  |  How to cite

Oncotarget. 2018; 9:26605-26615. https://doi.org/10.18632/oncotarget.24902

Metrics: PDF 1551 views  |   HTML 2375 views  |   ?  


Yan Hu1,*, Xiaoou Li1,*, Yacong An1, Jinhong Duan1 and Xian-Da Yang1

1Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100005, China

*These authors have contributed equally to this work

Correspondence to:

Xian-Da Yang, email: [email protected]

Keywords: CD19; aptamer; targeted therapy; lymphoma

Received: August 18, 2017    Accepted: February 26, 2018    Published: June 01, 2018


CD19 is overexpressed in most human B cell malignancies and considered an important tumor marker for diagnosis and treatment. Aptamers are oligonucleotides that may potentially serve as tumor-homing ligand for targeted cancer therapy with excellent affinity and specificity. In this study, we selected a novel CD19 aptamer (LC1) that was a 59-nucleotide single strand DNA. The aptamer could bind to recombinant CD19 protein with a Kd of 85.4 nM, and had minimal cross reactivity to bovine serum albumin (BSA) or ovalbumin (OVA). Moreover, the aptamer was found capable of binding with the CD19-positive lymphoma cells (Ramos and Raji), but not the CD19-negative cell lines (Jurkat and NB4). An aptamer-doxorubicin complex (Apt-Dox) was also formulated, and selectively delivered doxorubicin to CD19-positive lymphoma cells in vitro. The results indicate that aptamer LC1 can recognize CD19-positive tumor cells and may potentially function as a CD19-targeting ligand.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 24902